Ex-vivo Expanded γδ T-lymphocytes (OmnImmune®) in Patients With Acute Myeloid Leukaemia (AML)

Exclusion Criteria

• •5. Considered suitable for lymphodepleting chemotherapy
• •6. Age 18 years up to the age of 70 (≤ 70)
• •7. Life expectancy of at least 3 months
• •8. Karnofsky performance status ≥ 50%
• •9. Available related HLA-haploidentical or HLA-matched donor
• •10. Ability to be off systemic prednisone and other immunosuppressive drugs for at least 3 days prior to γδ T cells product infusion. Maintenance replacement steroid is allowed.
• •11. Patient able to understand and sign written informed consent
• •1. Uncontrolled infections
• •2. Renal insufficiency: creatinine \> 180 μmol/L or on dialysis
• •3. Heart failure: EF \< 40%
• •4. Respiratory insufficiency: oxygen therapy required at inclusion in the study
• •5. Significant liver impairment: bilirubin \> 50 μmol/L, AST or ALT \> 4 times normal upper limit
• •6. Treatment with bisphosphonates (2 months before start)
• •7. Active autoimmune disease or GvHD
• •8. Pregnant or breastfeeding
• •9. Patient of fertile age not using two-barrier method of birth control.